Retention of an albumin-bound furan dicarboxylic acid in patients with chronic renal failure or after a kidney transplant

Nephrology Dialysis Transplantation

Volumn 11, Issue 5, 1996, Pages 803-807

  Costigan, M G ^a   Yaqoob, M ^b   Lindup, W E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

3 carboxy 4 methyl 5 propyl 2 furanpropanoic acid; Albumin; Chronic renal failure; Furan dicarboxylic acid; Protein binding; Renal transplant

Indexed keywords

2 FUROIC ACID; ALBUMIN; ATENOLOL; BUMETANIDE; CAPTOPRIL; CREATININE; CYCLOSPORIN; FUROSEMIDE; HEMOGLOBIN; LABETALOL; NIFEDIPINE; PRAZOSIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; GRAFT FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENOVASCULAR HYPERTENSION; UREMIA;

EID: 0029919328     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027402     Document Type: Article

References (35)

1. Spiteller M, Spiteller G. Trennung und Charakterisierung Saurer Harnbestandteile J Chromatogr 1979; 164: 253-317
2. Pfordt J, Thoma H, Spiteller G. Identifizierung, Struktura-bleitung und Synthese bisher unbekannte Urofuransauren im menschlichen Blut. Lieb Ann Chem 1981; 2298-2308
3. Spiteller G. The way from physiological inactive excretion products to active compounds exemplified with urofuran acids. Iyo Masu Kenyukai Koenshu 1985; 10: 3-15
4. Hanneman K, Puchta V, Simon E. Ziegler H, Spiteller G. The common occurrence of furan fatty acids in plants. Lipids 1988; 24: 296-298
5. Gorst-Allman CP, Puchta V, Spiteller G. Investigations of the origin of the furan fatty acids (F-acids). Lipids 1988; 23: 1032-1036
6. Liebich HM, Pickert A, Tetschner B. Gas Chromatographic and gas chromatographic-mass spectrometric analysis of organic acids in plasma of patients with chronic renal failure. J Chromatogr 1984; 289: 259-266
7. Collier R, Lindup WE, Liebich HM, Spiteller G. Inhibitory effect of the uraemic metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid on plasma protein binding. Br J Clin Pharmacol 1986; 21: 610P
8. Lindup WE, Bishop KA, Collier R. Drug binding defect of uraemic plasma: contribution of endogenous binding inhibitors. In: Tillement JP, Lindenlaub E, eds. Protein Binding and Drug Transport. Schattauer Verlag. Stuttgart, 1986; 397-414
9. Collier R, Lindup WE Drug binding defect of uraemic plasma, inhibitory effect of furanoid acids. Br J Clin Pharmacol 1987; 23: 650P-651P
10. Barker CE, Lindup WE. Effect of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid on the binding of fluorescent probes to human albumin. Br J Clin Pharmacol 1989; 27: 675P
11. Mabuchi H, Nakahashi H. A major inhibitor of phenytoin binding to serum protein in uraemia. Nephron 1988; 48: 310-314
12. Henderson SJ, Lindup WE. Interaction of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia, with human albumin. Biochem Pharmacol 1990; 40: 2543-2548
13. Gulyassy PF, Depner TA. In depth review. Impaired binding of drugs and endogenous ligands in renal disease. Am J Kidney Dis 1983; 2: 578-601
14. Gulyassy PF, Jarrad EA, Stanfel LA. Contributions of hippurate, mdoxyl sulphate and o-hydroxyhippurate to impaired ligand binding by plasma in azotemic humans. Biochem Pharmacol 1987; 36: 4215-4220
15. Mabuchi H, Nakahashi H. Determination of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, a major endogenous ligand substance in uraemic serum, by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1987; 415: 110-117
16. Mabuchi H, Nakahashi H. Displacement by anionic drugs of endogenous ligands bound to albumin in uraemic serum. Ther Drug Monit 1988; 10: 261-264
17. Niwa T, Takeda N, Maeda K, Shibata M, Tatematsu A. Accumulation of furancarboxylic acids in uraemic serum as inhibitors of drug binding. Clin Chim Acta 1988; 173: 127-138
18. Lindup WE, Henderson SJ, Barker CE. Drug binding in renal disease. In: Belpaire F, Bogaert M, Tillement JP, Verbeeck R, eds. Plasma Binding of Drugs and Its Consequences. Academia Press, Ghent, 1991; 103-120
19. Henderson SJ, Lindup WE. Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uraemia. J Pharmacol Exp Ther 1992; 263: 54-60
20. Costigan MG, Gilchrist TL, Lindup WE. Inhibitors of plasma protein binding and the renal secretion of organic acids. Br J Clin Pharmacol 1992; 34: 175P-176P
21. Costigan MG, Lindup WE. Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uraemia. Kidney Int (in press)
22. Depner TA. Suppression of tubular anion transport by an inhibitor of serum protein binding in uraemia. Kidney Int 1981; 20: 511-518
23. Depner TA. Suppression of para-aminohippurate transport in the isolated perfused kidney by an inhibitor of serum protein binding in uremia. Am J Kidney Dis 1984; 3: 280-286
24. Lim C-F, Bernard BF, De Jong M, Docter R, Krenning EP, Hennemann G. A furan fatty acid and indoxyl sulphate are putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993; 76: 318-324
25. Costigan MG, O'Callaghan CA, Lindup WE. Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nepliron (in press)
26. Liebich HM, Risler T, Fischer U, Rapp K, Tetschner B, Eggstein M. Gas Chromatographic determination of hippuric acid and a furancarboxylic acid in plasma of patients with kidney diseases. J Chromatogr 1987; 399: 291-294
27. Liebich HM, Bubeck JI, Pickert A, Wahl G, Scheiter A. Hippuric acid and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in serum and urine. Analytical approaches and clinical relevance in kidney diseases. J Chromatogr 1990; 500: 615-627
28. Pickert A, Baherle A, Liebich HM. Determination of hippuric acid and furanoic acid in serum of dialysis patients and control persons by high-performance liquid chromatography. J Chromatogr 1989; 495: 95-104
29. Mabuchi H, Nakahashi H, Hamajima T, Aikawa ?, Oka T. The effect of renal transplantation on a major endogenous ligand retained in uremic serum. Am J Kidney Dis 1989; 13: 49-54
30. Niwa T, Yazawa T, Kodama T, Uehara Y, Maeda K, Yamada K. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 1990; 56: 241-245
31. Costigan MG, Gilchrist TL, Lindup WE. Synthesis and physicochemical properties of the furan dicarboxylic acid. 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, an inhibitor of plasma protein binding in uraemia. J Pharm Pharmacol (in press)
32. Costigan MG, Yaqoob M, Lindup WE. Effects of haemodialysis and continuous ambulatory peritoneal dialysis on the plasma clearance of an albumin-bound furan dicarboxylic acid. Nephrol Dial Transplant 1995; 10: 648-652
33. Barry JM. Immunosuppressive drugs in renal transplantation. Drugs 1992; 44: 554-556
34. Morris PJ. Cyclosporine. In: Morris PJ, ed. Kidney Transplantation: Principles and Practice. 4th edn. WB Saunders, Philadelphia. 1994; 179-201
35. Marcen R, Gallego N, Gamez C, Orofino L, Ortuno J. Hyperuricemia after kidney transplantation in patients treated with cyclosporin. Am J Med 1992; 93. 354-355